Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Adaptimmune Therapeutics PLC changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 69 | 65 | −4 |
| Shares | 114.0M | 116.0M | +2.01M (+1.8%) |
| Value | $166.3M | $126.4M | −$39.9M (−24.0%) |
New holders (6)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Simplify Asset Management Inc. | 150,000 | $163.5K | 0.03% |
| Captrust Financial Advisors | 21,622 | $23.6K | 0.00% |
| HRT Financial LP | 18,047 | $19.0K | 0.00% |
| Bayesian Capital Management, LP | 14,786 | $16.1K | 0.00% |
| Commonwealth of Pennsylvania Public School Empls Retrmt Sys | 14,287 | $15.6K | 0.00% |
| Global Retirement Partners, LLC | 6,000 | $8.40K | 0.00% |
Sold out (10)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Kettle Hill Capital Management, LLC | 261,411 | $381.7K |
| Marshall Wace, LLP | 89,171 | $130.2K |
| HBK Sorce Advisory LLC | 70,000 | $65.0K |
| Kapitalo Investimentos Ltda | 36,400 | $53.1K |
| Arrowstreet Capital, Limited Partnership | 32,586 | $48.0K |
| Susquehanna International Group, LLP | 28,126 | $41.1K |
| Caxton Associates LP | 25,713 | $37.5K |
| StoneX Group Inc. | 11,431 | $16.7K |
| Rockefeller Capital Management L.P. | 2,000 | $2.00K |
| Signaturefd, LLC | 373 | $545 |